Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECIR: Extracorporeal Photopheresis for Steroid-Refractory irAEs After Checkpoint Inhibitors
2024-513614-36-00Phase 2Completed
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methoxsalen in immune-mediated colitis, Immune-Related Hepatitis (irH), immune-mediated pneumonitis and 1 more, sponsored by Universitätsklinikum Freiburg. Primary endpoint: Rate of treatment-related adverse events and serious adverse events. Started Jul 2022; status: completed.
02
Drugs
methoxsalen
03
Conditions
immune-mediated colitisImmune-Related Hepatitis (irH)immune-mediated pneumonitisimmune-related dermatitis
Beyond the preview
Go deeper on 2024-513614-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513614-36-00.